Ibrutinib Continues to Outperform Chemoimmunotherapy in Patients With Treatment-Naïve CLL

Ibrutinib was associated with prolonged progression-free survival (PFS) compared to the chemoimmunotherapy regimen bendamustine plus rituximab in older patients with treatment-naïve chronic lymphocytic leukemia (CLL). In...